Close

Anti-WT1 (RMFPNAPYL) TCR-Like Antibody (Q2L), HLA-A*0201-Restricted (TCR-LA-ZP149)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

TCR-like monoclonal antibodies (TCR-like mAbs), which recognise a specific peptide in association with an MHC molecule (human leukocyte antigen, HLA in humans), permit the targeting of such inaccessible nuclear or cytoplasmic tumor- or virus-associated antigens based on binding to their MHC-presented peptides found on the surface of target cells. Since they allow, for the first time, visualization of MHC/peptide complexes on various cells in health and disease, they belong to a new class of antibodies which can be utilized as important tools in molecular immunology.Creative Biolabs has been raised against peptides from many of such antigens. This TCR-like antibody specifically targets to HumanQ2L antigen that recognizes epitope RMFPNAPYL presented on HLA-A*0201. This product is mainly used to treat Cancer.

Specific Inquiry

  • Size:
  • Form:
  Add to Cart

Details

  • Target
  • WT1
  • Targeting Cell Type
  • Tumor Cell
  • HLA
  • HLA-A*0201
  • Affinity
  • 263 nM
  • Epitope
  • RMFPNAPYL
  • Format
  • IgG
  • Targeting Diseases
  • Cancer

Target

  • Clone
  • Q2L
  • Expression
  • Yeast
  • Target Species
  • Human
  • Gene Name
  • WT1 transcription factor
  • Synonyms
  • AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1, WT33

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-WT1 (RMFPNAPYL) TCR-Like Antibody (Q2L), HLA-A*0201-Restricted (TCR-LA-ZP149). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.